#USA #Hamilton #Ac-225 #AtomVie #IONETIX

AtomVie Global Radiopharma and Ionetix Corporation: A Strategic Partnership for Radiopharmaceutical Advancements

In a significant move for the radiopharmaceutical industry, AtomVie Global Radiopharma has secured a supply agreement with Ionetix Corporation. This collaboration marks a pivotal advancement in the development of Actinium 225 (Ac-225) radiotherapeutics, enabling AtomVie to bolster its capabilities in providing innovative solutions for targeted therapies.

What This Partnership Entails

Under this newly established agreement, Ionetix will supply cGMP-grade Ac-225, an alpha-emitting radioisotope, to AtomVie, playing a vital role in the development and manufacturing of various clients' radiopharmaceutical programs. The partnership is designed to enhance AtomVie’s service offerings and expand its ability to support a burgeoning pipeline of therapies that rely on alpha-emitting compounds.

As AtomVie prepares to unveil its state-of-the-art facility, the demand for reliable supplies of therapeutic isotopes has surged. Securing high-quality isotopes like Ac-225 is crucial for facilitating the transition of clients' programs from research phases into clinical development. In this context, the partnership with Ionetix is timely and strategic, reflecting a keen understanding of the industry's needs.

Leadership Insights

Bruno Paquin, the Chief Executive Officer of AtomVie, emphasized the importance of this partnership, stating, "Reliable access to high-quality alpha-emitting isotopes like Ac-225 is essential for the next generation of targeted radiopharmaceuticals." This collaboration not only enhances AtomVie’s capacity to support clients involved in the development of innovative alpha-therapies but also ensures that the supply chain remains secure as they gear up for operations at their new facility.

The new radiopharmaceutical manufacturing facility, which has been specifically designed for GMP operations, is on track for operational readiness in the first quarter of 2026. This development promises to significantly contribute to meeting the growing global demand for radiotherapeutics.

Ionetix’s Role and Commitment

David Eve, Vice President of Medical Affairs at Ionetix, expressed enthusiasm regarding the partnership, stating, "We are proud to partner with AtomVie at a time when the field of targeted radiopharmaceuticals is accelerating." By providing Ac-225 for clinical use, Ionetix reinforces its commitment to supporting a more reliable and scalable pathway for companies developing promising alpha-therapies for patients in need.

Both organizations are united by a shared vision of driving radiopharmaceutical innovation and addressing the increasing demand for alpha-therapy development worldwide. This agreement exemplifies a strong partnership where scientific excellence meets commercial need, ultimately benefiting patients who require advanced therapeutic options.

About AtomVie Global Radiopharma

AtomVie is a reputed global Contract Development and Manufacturing Organization (CDMO) specializing in the GMP manufacturing and distribution of clinical and commercial radiopharmaceuticals. With extensive scientific, technical, regulatory, and logistical expertise, AtomVie offers a comprehensive suite of services, catering to clients across over 28 countries.

The current expansion initiative includes the establishment of a new 72,300 square-foot facility, reinforcing AtomVie’s position as a leader in the radiopharmaceutical sector. This facility will enhance their operational capabilities and support the clinical studies and trials necessary for bringing innovative therapies to market.

Conclusion

The collaboration between AtomVie Global Radiopharma and Ionetix Corporation is a significant step forward in the radiopharmaceutical landscape. This partnership not only enhances both companies' operational capabilities but also ensures that they are well-equipped to meet the therapeutic needs of the future, fostering innovation and growth within the healthcare industry.